AARD · NASDAQ

Aardvark Therapeutics, Inc.

Q: How do I get AARD news from the API?

Call GET /v1/news?tickers=AARD. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

$1.40 -0.48 (-10.88%)

Company overview

Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic diseases. Its lead product candidate, ARD-101, is an oral gut-restricted small-molecule agonist targeting bitter taste receptors expressed in the gut lumen. It is in Phase III clinical trials for hyperphagia associated with Prader-Willi Syndrome and in Phase II clinical trials for hyperphagia associated with acquired hypothalamic obesity resulting from treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in Phase I clinical trials for obesity treatment. Incorporated in 2017 and based in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $30.6M
Employees: 22
Headquarters: San Diego, CA
Website: aardvarktherapeutics.com
CEO: Tien-Li Lee
Listed: February 13, 2025
P/E: -0.44
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: $0.00
Operating income: -$74.7M
EBITDA: -$74.7M
Net income: -$69.9M
EPS: -$3.21
Total assets: $98.6M
Total debt: $336,000
Earnings yield: -229.29%

Price chart

AARD 1D NASDAQ O2.80H2.83L1.43C1.46-2.50 (-63.16%)Vol3.76M

News

Ticker	Type	Headline	Source	Published
AARD	Stock news	Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript	Seeking Alpha	Oct 23, 7:17:15 PM ET
AARD	Stock news	Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient	Benzinga	Oct 23, 11:43:43 AM ET
AARD	Press release	Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials	GlobeNewswire	Oct 23, 7:00:00 AM ET
AARD	Press release	Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data	GlobeNewswire	Oct 22, 4:05:00 PM ET
AARD	Legal	Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); and New Era Energy & Digital, Inc.	GlobeNewswire	Oct 21, 8:24:48 AM ET
AARD	Legal	Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Bank of America Corporation (NYSE: BAC); Coastal Financial Corporation (NASDAQ: CCB); and Erasca, Inc.	GlobeNewswire	Oct 20, 8:40:26 AM ET
AARD	Legal	Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Hub Group, Inc. (NASDAQ: HUBG); and Power Solutions International, Inc.	GlobeNewswire	Oct 19, 7:00:00 AM ET
AARD	Stock news	Aardvark Therapeutics, Inc. (AARD) – What Are Analysts Thinking About This Stock?	Defense World	Oct 18, 2:15:18 AM ET
AARD	Legal	Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc.	GlobeNewswire	Oct 15, 8:30:40 AM ET
AARD	Legal	Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); New Era Energy & Digital, Inc.	GlobeNewswire	Oct 14, 9:53:04 AM ET
AARD	Legal	Pomerantz LLP Announces Class Action Litigation Filing Against Aardvark Therapeutics, Inc. – AARD	ACCESS Newswire	Oct 14, 7:00:00 AM ET
AARD	Legal	Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD	GlobeNewswire	Oct 13, 4:17:05 PM ET
AARD	Legal	AARD DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARD	Newsfile Corp	Oct 13, 3:53:00 PM ET
AARD	Legal	SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD	GlobeNewswire	Oct 13, 1:10:08 PM ET
AARD	Legal	Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm	GlobeNewswire	Oct 13, 12:00:00 PM ET
AARD	Legal	CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026	Business Wire	Oct 13, 9:48:00 AM ET
AARD	Legal	Class Action Lawsuit Alert: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. (AARD) Investors of October 13, 2026 Deadline	ACCESS Newswire	Oct 13, 1:20:00 AM ET
AARD	Legal	October 13, 2026 Deadline: Join Class Action Lawsuit Against Aardvark Therapeutics, Inc. (AARD) - Contact Levi & Korsinsky	ACCESS Newswire	Oct 13, 1:00:00 AM ET
AARD	Legal	Class Action Now Underway by Pomerantz LLP Against Aardvark Therapeutics, Inc. – AARD	ACCESS Newswire	Oct 12, 6:00:00 PM ET
AARD	Legal	AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc.	PR Newswire	Oct 12, 5:34:00 PM ET

FAQ

Questions about Aardvark Therapeutics, Inc.

What does Aardvark Therapeutics, Inc. do?

What is AARD's market cap?

Aardvark Therapeutics, Inc. (AARD) is a listed stock with a live quote. The latest market cap on this page is $30.6M.

Where is Aardvark Therapeutics, Inc. headquartered?

Aardvark Therapeutics, Inc. is headquartered in San Diego, CA.

How do I get AARD news from the API?

Call GET /v1/news?tickers=AARD. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

How far back does AARD news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AARD, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.

Is the AARD price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs